1025967-78-5 | L-Phenylalanine, N-[[2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl]carbonyl]-3-(methylsulfonyl)-

Packsize	Purity	Availability	Price	Discounted Price
10mg	95%	in stock	$25.00	$18.00
25mg	95%	in stock	$40.00	$28.00
50mg	95%	in stock	$60.00	$42.00
100mg	95%	in stock	$74.00	$52.00
250mg	95%	in stock	$139.00	$97.00
1g	95%	in stock	$341.00	$239.00
3g	95%	in stock	$788.00	$552.00
5g	95%	in stock	$1,132.00	$793.00

Description

• Catalog Number: AA09982
• Chemical Name: L-Phenylalanine, N-[[2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl]carbonyl]-3-(methylsulfonyl)-
• CAS Number: 1025967-78-5
• Molecular Formula: C29H24Cl2N2O7S
• Molecular Weight: 615.4811
• MDL Number: MFCD28502439
• SMILES: OC(=O)[C@@H](NC(=O)c1c(Cl)cc2c(c1Cl)CCN(C2)C(=O)c1ccc2c(c1)occ2)Cc1cccc(c1)S(=O)(=O)C

Computed Properties

• Complexity: 1100
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 41
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 7
• XLogP3: 4.7

Literature

• Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).

  Ophthalmology 20170101

• Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease.

  Drugs of today (Barcelona, Spain : 1998) 20160901

• Lifitegrast: A novel drug for treatment of dry eye disease.

  Journal of pharmacology & pharmacotherapeutics 20160101

• Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.

  Ophthalmology 20151201

• Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.

  Ophthalmology 20140201

• Integrin modulators: a patent review.

  Expert opinion on therapeutic patents 20131001

• Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study.

  Eye (London, England) 20120701

• Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.

  ACS medicinal chemistry letters 20120308

• Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.

  Biochimica et biophysica acta 20110801

• The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs.

  Investigative ophthalmology & visual science 20110516

• Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adults.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20110201

• Tear cytokine profiles in dysfunctional tear syndrome.

  American journal of ophthalmology 20090201

• LFA-1 as a key regulator of immune function: approaches toward the development of LFA-1-based therapeutics.

  Current pharmaceutical design 20060101